April 7 (Reuters) - OS Therapies Inc OSTX.A:
OS THERAPIES REQUESTS MEETING WITH FDA TO GAIN AGREEMENT ON SURROGATE ENDPOINT$(S)$ FOR BREAKTHROUGH THERAPY DESIGNATION & ACCELERATED APPROVAL OF OST-HER2 IN THE PREVENTION OF RECURRENCE OF FULLY RESECTED, LUNG METASTATIC OSTEOSARCOMA
OS THERAPIES: APPLIES FOR MEETING PER FDA SUGGESTION RECEIVED ON APRIL 2, 2025
OS THERAPIES -SUFFICIENT CASH ON HAND TO OPERATE INTO MID-2026
OS THERAPIES: MEETING IS EXPECTED TO OCCUR IN Q2 OF 2025
OS THERAPIES: INTENDS TO INITIATE ROLLING BLA SUBMISSION WITH POTENTIAL TO GET ACCELERATED APPROVAL AS EARLY AS YEAR-END 2025
Source text: ID:nBw21PR7wa
Further company coverage: OSTX.A
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.